Buy & Sell Hershey Co (HSY) – Hershey Co Price Today
Key Stats
- $37.93BMarket Cap
- Consumer StaplesSector
- -22.97%3M Drawdown
- $42.73BEnterprise Value
- 3.11%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 131 daysTypical Hold Time
Hershey Co (HSY) is currently valued at a market capitalization of $37.93B, with an enterprise value of $42.73B. Over the past 52 weeks, Hershey Co has traded between a low of $151.29 and a high of $236.28, highlighting its annual price range. Over the past three months, Hershey Co has recorded a drawdown of -22.97%, reflecting recent price volatility. Hershey Co offers a dividend yield of 3.11%, with the most recent dividend of $1.45 paid on 15 May 26. On average, investors hold Hershey Co for approximately 131 days, indicating typical investor behavior on the platform.
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Small-cap ETFs may rebound as investors overlook them amid mega-cap tech focus, creating potential buying opportunities.
Small-cap stocks are starting to outperform again, but ETF investors remain focused on mega-cap technology and AI stocks, leading to small-cap ETFs holding only about 4% of ETF assets down from 10%. Despite $25 billion outflows from small-cap mutual ...